Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Low-dose thalidomide in patients with metastatic renal cell carcinoma.

Tunio MA, Hashmi A, Qayyum A, Naimatullah N, Masood R.

J Pak Med Assoc. 2012 Sep;62(9):876-9.

2.

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.

Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R.

Cancer. 2002 Aug 15;95(4):758-65.

3.

Phase II trial of thalidomide in renal-cell carcinoma.

Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A.

Ann Oncol. 2002 Jul;13(7):1029-35.

PMID:
12176780
4.

The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.

Harshman LC, Li M, Srinivas S.

Am J Clin Oncol. 2008 Oct;31(5):417-23. doi: 10.1097/COC.0b013e318168ef47.

PMID:
18838876
5.

[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].

Schrader AJ, Heidenreich A, Hegele A, Olbert P, Varga Z, Hofmann R.

Aktuelle Urol. 2006 Nov;37(6):429-35; quiz 423-4. German.

PMID:
17099831
6.

Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.

Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM.

Urology. 2004 Jun;63(6):1061-5.

PMID:
15183950
7.
8.

Lenalidomide therapy for metastatic renal cell carcinoma.

Amato RJ, Hernandez-McClain J, Saxena S, Khan M.

Am J Clin Oncol. 2008 Jun;31(3):244-9. doi: 10.1097/COC.0b013e31815e451f.

PMID:
18525302
9.

Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.

Kerst JM, Bex A, Mallo H, Dewit L, Haanen JB, Boogerd W, Teertstra HJ, de Gast GC.

Cancer Immunol Immunother. 2005 Sep;54(9):926-31. Epub 2005 May 19.

PMID:
15906025
10.

The treatment of advanced renal cell cancer with high-dose oral thalidomide.

Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, Mak I, Sapunar F, Ahern R, Gore ME.

Br J Cancer. 2001 Sep 28;85(7):953-8.

11.
12.

Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.

Lee CP, Patel PM, Selby PJ, Hancock BW, Mak I, Pyle L, James MG, Beirne DA, Steeds S, A'Hern R, Gore ME, Eisen T.

J Clin Oncol. 2006 Feb 20;24(6):898-903.

PMID:
16484699
13.
14.

Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide.

Kraemer A, Hauser S, Kim Y, Gorschl├╝ter M, M├╝ller SC, Brossart P, Schmidt-Wolf IG.

Ger Med Sci. 2009 Jun 10;7:Doc04. doi: 10.3205/000063.

15.

Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.

Vaishampayan UN, Heilbrun LK, Shields AF, Lawhorn-Crews J, Baranowski K, Smith D, Flaherty LE.

Invest New Drugs. 2007 Feb;25(1):69-75. Epub 2006 Aug 26.

PMID:
16937078
16.
17.

Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.

Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ.

Clin Genitourin Cancer. 2013 Mar;11(1):45-50. doi: 10.1016/j.clgc.2012.06.001. Epub 2012 Oct 4.

PMID:
23041453
18.
19.

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.

Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM.

Cancer. 2006 Dec 1;107(11):2609-16.

20.

Thalidomide therapy for renal cell carcinoma.

Amato RJ.

Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S59-65. Review.

PMID:
12850528

Supplemental Content

Support Center